| Name | ethyl (2S)-2-[(2-bromo-3-oxospiro[3.5]non-1-en-1-yl)amino]-3-[4-(2,7-naphthyridin-1-ylamino)phenyl]propanoate |
|---|---|
| Synonyms |
ethyl-(2S)-2-(2-bromo-3-oxospiro[3,5]non-1-en-1-ylamino)-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoate
(S)-ethyl-3-(4-(2,7-naphthyridin-1-ylamino)phenyl)-2-(2-bromo-3-oxospiro[3.5]non-1-en-1-ylamino)propanoate Zaurategrast ethyl ester ethyl 2(S)-(2-bromo-3-oxo-spiro[3.5]non-1-en-1-ylamino)-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoate L-Phenylalanine,N-(2-bromo-3-oxospiro(3.5)non-1-en-1-yl)-4-(2,7-naphthyridin-1-ylamino)-,ethyl ester |
| Description | Zaurategrast ethyl ester (CDP323), the ethyl ester prodrug of CT7758[1], is a α4β1/α4β7 integrin antagonist used for the treatment of inflammatory and autoimmune disorders[2]. |
|---|---|
| Related Catalog | |
| Target |
α4β1/α4β7 integrin[1] |
| In Vitro | Zaurategrast ethyl ester (CDP323), an ethyl ester prodrug of CT7758, shows some improvements in increasing mass transfer[1]. |
| References |
| Molecular Formula | C28H29BrN4O3 |
|---|---|
| Molecular Weight | 549.46 |
| Exact Mass | 548.14200 |
| PSA | 93.21000 |
| LogP | 6.04080 |
| Storage condition | 2-8℃ |
|
~91%
455264-30-9 |
| Literature: CELLTECH R and D LIMITED Patent: WO2004/7428 A1, 2004 ; Location in patent: Page 56 ; |
|
~%
455264-30-9 |
| Literature: Schuele, Arnaud; Ates, Celal; Palacio, Magali; Stofferis, Jimmy; Delatinne, Jean-Pierre; Martin, Bruno; Lloyd, Steven Organic Process Research and Development, 2010 , vol. 14, # 4 p. 1008 - 1014 |
| Precursor 1 | |
|---|---|
| DownStream 1 | |